By Dr. David A. Jernigan
Initial test results are very promising that the newly discovered Induced Native Phage Therapy (INPT)* may indeed cause phages to attack and eliminate all of the targeted Borrelia bacteria, within an unprecedented five days, with minimal Jarish-Herxheimer reaction worsening. The idea of truly eliminating 100% of the bacteria within a week is remarkable, especially contrasting the present drug and botanical models of treatment that require months to years of numerous antibiotics and difficult Herx reactions.
INPT can be viewed in the same manner as one would think of stimulating the immune system. Instead of stimulating the body’s immune cells by nutritional, manipulative, bioenergetic, or botanical methods, INPT is stimulating existing phages within the body as an untapped alternate immune defense against infections.
In a recent article reported here I presented the hypothesis that naturally-occurring, or native phages, could be induced to specifically and rapidly target and kill all of the Borrelia in the body, penetrating and killing even those bacteria hidden behind biofilms, and cross the Blood-Brain-Barrier to reach brain infections. A proprietary bioenergetic process was developed in November of 2019, called Induced Native Phage Therapy (INPT) which with ongoing testing is moving from hypothesis to clinical theory.
Phages are ubiquitous in nature, causing an estimated trillion-trillion microbial infections per second! The difference in nature, without stimulation, these phages will most often only kill 40% of their host bacteria. It is clear from almost 100 years of phage treatments, that phages under the right situation can annihilate 100% of their host, resulting in dramatic cures of the patient suffering from an infection of that bacteria.
Although phages have been used for many years to fight antibiotic-resistant bacteria, no one has conceived that every bacterial infection that enters the human body is already infected with its own specific type of phage infection, what we are calling native phages, which persist as long as their bacterial host survives. (Read here the known and new science of phages) The driving and new concept behind INPT is that these native phages could be bio-energetically induced to rapidly and completely destroy their host bacteria. The stimulating, or inducing of these native phages is unique to the INPT process.
Historically conventional phage treatments have focused on finding and introducing phages from outside the body which are introduced by the treating doctor into the patient, usually in a cocktail of several types of phages hoped to eliminate the pathogenic bacteria in the patient. This process is tedious and is great when it works, but requires much trial and error of finding a match of the exact phage or phages that will kill the patient’s infection.
The Newest and Most Sensitive Lyme Testing
The newest, most sensitive, and accurate lab test for acute or chronic infection with any of the 20 different strains of Borrelia spirochetes, such as B. burgdorferi, B. miyamotoi, B. hermsii, B. duttonii, etc., collectively the causative bacteria of Lyme disease, is the Phelix Borrelia-Phage test developed by R.E.D. Laboratory in Belgium.
The Phelix Borrelia-Phage test is so accurate because it is a qPCR test that seeks to find the DNA of Borrelia-Phages. These are bacteriophages, often shortened to phages, which are a type of virus that specifically and only targets Borrelia bacteria as a host to replicate more phages. Anytime you have Borrelia bacteria in your body, you will definitely have Borrelia-phages. Unlike the Lyme spirochetes, which are often difficult to find with conventional lab testing, the Borrelia-phages are quite easy to detect.
Conventional lab tests are looking for the DNA of the spirochetes or the antibodies to the Borrelia spirochetes, both of which are often undetectable by the conventional Lyme Western-blot and PCR testing, causing many false-negative test results. Many people have been incorrectly told that they do not have Lyme disease due to the inaccuracy of these tests.
Turning Hypothesis into Clinical Theory
To date, a total of 14 people, with acute and chronic Lyme disease (Borreliosis), from multiple states in the U.S. and other countries, have had their blood drawn for the first of a series of three Phelix Borrelia-Phage testing. The blood for the initial test was drawn one to two days after starting INPT targeting of their Borrelia. This initial challenge is to increase the number of detectable phages as they attack and kill the Borrelia. All of the initial Phelix Borrelia-Phage tests were found to be positive.
The second Phelix test took place roughly two weeks after the initial test. It was decided that although it is believed that the Borrelia were completely gone within five days, according to the laboratory findings, it requires 3-5 days for all of the Borrelia-phages to die off after the last of the Borrelia spirochetes are dead. Without the Borrelia spirochetes to manufacture more of the Borrelia phages, the phages cannot survive.
In this second Phelix test, the first person’s test result is just in and reported as negative, verifying the bacteria have been eliminated. This result was double confirmed by the laboratory, with a very high confidence in the result due to the nature of high specificity and high sensitivity of the Phelix Borrelia-Phage test.
A third Phelix test is planned after at least 45 days have passed from the second test. This will allow 2-3 replication cycles of any potential residual Borrelia. A negative finding on this third test will help to verify the idea of complete annihilation of the Borrelia from all parts of the body.
From earlier work it appears that phages can be induced to also kill the Lyme “persistor” cells/cysts.
The attraction of this work is obvious, however it is even more exciting when considering that if verified with continued INPT treatment and phage testing, the reality is that when there are no Borrelia bacteria or persistor cells left, a person will not be not in remission, as seen with conventional antibiotic treatment when symptoms abate for a period, but because a few bacteria remain in spite of prolonged antibiotic treatment, their illness may return. With none of the Borrelia left in the body, there is no remission, as the person is cured. Reinfection would require the person to acquire the infection by one of the many transmitting vectors, such as ticks.
The historical use of phages and the incredible speed of recovery often seen from severe infections is well-documented in the literature, at times eliminating the target bacteria within two days. More INPT/Phelix testing will be ongoing, however these initial results of INPT appear to be very encouraging. INPT may usher in a new era of bioelectrical/bioinformatics in medicine to induce phages to address much more than infections.
The delivery of the INPT treatment has been well-tolerated, even by people who are sensitive to almost all medicines, making it ideal for those with MCS, MCAS, and other hypersensitivity conditions.
The way phages kill a microbe causes much less “die-off” worsening of a person’s symptoms than antibiotics and other antimicrobial products. We now know from research that a “Herx” reaction is not actually from the bacterial guts spilling into the body as the bacteria are killed as with antibiotics. A Herx reaction is due to the proinflammatory cytokines released by the body’s immune cells that engulfed the dying bacteria. With phage killing of the bacteria the bacteria explodes where it sits and only the debris is cleaned up by the immune cells. The debris doesn’t cause much of a proinflammatory cytokine release and therefore the best treatment outcome is possible, faster and complete annihilation of the target microbe, with less worsening of the patient’s symptoms.
INPT is being used at the Biologix Center for Optimum Health to target any microbial issue, even mold and parasite infections, however the only phage lab test available at this time is for Borrelia strains. Researchers are working to develop phage lab tests for Bartonella and other types of microbes.
The clinical symptomatic improvements in people receiving these treatments is often remarkable, lending further proof of concept.
*INPT is an innovation developed by Dr. David A. Jernigan, D.N.M, D.C., the founder and CEO of the Biologix Center for Optimum Health, in Franklin, Tennessee. An IRB Retrospective Registry is in place to publish peer-reviewed articles as this clinical work progresses. There are no financial or academic conflicts to be reported between Biologix and RED Lab.